• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

SARS-CoV-2 疫苗:哪些指标与全球首次接种剂量的分布有关。

SARS-COV-2 Vaccines: What Indicators are Associated with the Worldwide Distribution of the First Doses.

机构信息

Departamento de Administração, 67744Federal Rural University of Pernambuco, Recife, Brazil.

Departamento de Psicologia Cognitiva, 28116Federal University of Pernambuco, Recife, Brazil.

出版信息

Inquiry. 2021 Jan-Dec;58:469580211060184. doi: 10.1177/00469580211060184.

DOI:10.1177/00469580211060184
PMID:34823403
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8649438/
Abstract

The present study aimed to identify the factors associated with the distribution of the first doses of the COVID-19 vaccine. In this study, we used 9 variables: human development index (HDI), gross domestic product (GDP per capita), Gini index, population density, extreme poverty, life expectancy, COVID cases, COVID deaths, and reproduction rate. The time period was until February 1, 2021. The variable of interest was the sum of the days after the vaccine arrived in the countries. Pearson's correlation coefficients were calculated, and t-test was performed between the groups that received and did not receive the immunizer, and finally, a stepwise linear regression model was used. 58 (30.4%) of the 191 countries received the SARS-CoV-2 vaccine. The countries that received the most doses were the United States, China, the United Kingdom, and Israel. Vaccine access in days showed a positive Pearson correlation HDI, GDP, life expectancy, COVID-19 cases, deaths, and reproduction rate. Human development level, COVID-19 deaths, GDP per capita, and population density are able to explain almost 50% of the speed of access to immunizers. Countries with higher HDI and per capita income obtained priority access.

摘要

本研究旨在确定与 COVID-19 疫苗首剂分布相关的因素。本研究使用了 9 个变量:人类发展指数(HDI)、国内生产总值(人均 GDP)、基尼指数、人口密度、极端贫困、预期寿命、COVID 病例、COVID 死亡和繁殖率。时间范围截至 2021 年 2 月 1 日。感兴趣的变量是疫苗抵达各国后的天数总和。计算了 Pearson 相关系数,并对接受和未接受免疫剂的组进行了 t 检验,最后使用逐步线性回归模型。191 个国家中的 58 个(30.4%)接种了 SARS-CoV-2 疫苗。接种疫苗最多的国家是美国、中国、英国和以色列。疫苗接种天数呈正 Pearson 相关 HDI、GDP、预期寿命、COVID-19 病例、死亡和繁殖率。人类发展水平、COVID-19 死亡、人均 GDP 和人口密度能够解释接近 50%的疫苗接种速度。人类发展指数和人均收入较高的国家优先获得疫苗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d98b/8649438/514d1665a06f/10.1177_00469580211060184-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d98b/8649438/6d9a088c576d/10.1177_00469580211060184-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d98b/8649438/f7e8b7fd1af6/10.1177_00469580211060184-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d98b/8649438/de9f3a27a78b/10.1177_00469580211060184-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d98b/8649438/514d1665a06f/10.1177_00469580211060184-fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d98b/8649438/6d9a088c576d/10.1177_00469580211060184-fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d98b/8649438/f7e8b7fd1af6/10.1177_00469580211060184-fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d98b/8649438/de9f3a27a78b/10.1177_00469580211060184-fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d98b/8649438/514d1665a06f/10.1177_00469580211060184-fig4.jpg

相似文献

1
SARS-COV-2 Vaccines: What Indicators are Associated with the Worldwide Distribution of the First Doses.SARS-CoV-2 疫苗:哪些指标与全球首次接种剂量的分布有关。
Inquiry. 2021 Jan-Dec;58:469580211060184. doi: 10.1177/00469580211060184.
2
Determinants of access to the SARS-CoV-2 vaccine: a preliminary approach.SARS-CoV-2 疫苗可及性的决定因素:初步探讨。
Int J Equity Health. 2021 Aug 14;20(1):183. doi: 10.1186/s12939-021-01520-4.
3
COVAX and equitable access to COVID-19 vaccines.新冠疫苗实施计划与公平获取疫苗。
Bull World Health Organ. 2022 May 1;100(5):315-328. doi: 10.2471/BLT.21.287516. Epub 2022 Mar 25.
4
Associating the Change in New COVID-19 Cases to GDP per Capita in 38 European Countries in the First Wave of the Pandemic.将大流行第一波期间 38 个欧洲国家的人均 GDP 与新增 COVID-19 病例的变化相关联。
Front Public Health. 2021 Jan 20;8:582140. doi: 10.3389/fpubh.2020.582140. eCollection 2020.
5
COVID-19 Vaccine Diplomacy and Equitable Access to Vaccines Amid Ongoing Pandemic.COVID-19 疫苗外交与大流行期间公平获取疫苗
Arch Med Res. 2021 Oct;52(7):761-763. doi: 10.1016/j.arcmed.2021.04.006. Epub 2021 Apr 23.
6
Dialysis, COVID-19, Poverty, and Race in Greater Chicago: An Ecological Analysis.芝加哥大都会区的透析、新冠疫情、贫困与种族:一项生态分析
Kidney Med. 2020 Sep-Oct;2(5):552-558.e1. doi: 10.1016/j.xkme.2020.06.005. Epub 2020 Jul 30.
7
Association between COVID-19 morbidity, mortality, and gross domestic product, overweight/ obesity, non-communicable diseases, vaccination rate: A cross-sectional study.新冠肺炎发病率、死亡率与国内生产总值、超重/肥胖、非传染性疾病、疫苗接种率的关系:一项横断面研究。
J Infect Public Health. 2022 Feb;15(2):255-260. doi: 10.1016/j.jiph.2022.01.009. Epub 2022 Jan 14.
8
Reserving coronavirus disease 2019 vaccines for global access: cross sectional analysis.预留 2019 冠状病毒病疫苗以实现全球可及:横断面分析。
BMJ. 2020 Dec 15;371:m4750. doi: 10.1136/bmj.m4750.
9
The impact of delayed access to COVID-19 vaccines in low- and lower-middle-income countries.新冠疫苗在中低收入国家延迟接种的影响。
Front Public Health. 2023 Jan 12;10:1087138. doi: 10.3389/fpubh.2022.1087138. eCollection 2022.
10
Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.辉瑞-生物科技和 Moderna 疫苗在 SARS-CoV-2 B.1.617.2(Delta)变异株广泛传播之前和期间预防养老院居民感染 SARS-CoV-2 的有效性 - 国家医疗保健安全网络,2021 年 3 月 1 日至 8 月 1 日。
MMWR Morb Mortal Wkly Rep. 2021 Aug 27;70(34):1163-1166. doi: 10.15585/mmwr.mm7034e3.

引用本文的文献

1
The impact of social cohesion and risk communication on excess mortality due to COVID-19 in 213 countries: a retrospective analysis.社会凝聚力和风险沟通对 213 个国家 COVID-19 超额死亡率的影响:回顾性分析。
BMC Public Health. 2024 Jun 14;24(1):1598. doi: 10.1186/s12889-024-19076-7.
2
National governance and excess mortality due to COVID-19 in 213 countries: a retrospective analysis and perspectives on future pandemics.213 个国家的国家治理与 COVID-19 超额死亡:回顾性分析与未来大流行的展望。
Global Health. 2023 Oct 31;19(1):80. doi: 10.1186/s12992-023-00982-1.
3
Sociodemographic Factors Associated with COVID-19 Vaccination among People in Guatemalan Municipalities.

本文引用的文献

1
Covax must go beyond proportional allocation of covid vaccines to ensure fair and equitable access.新冠疫苗全球获取机制(Covax)必须超越新冠疫苗的按比例分配,以确保公平和平等的获取。
BMJ. 2021 Jan 5;372:m4853. doi: 10.1136/bmj.m4853.
2
How COVID vaccines are being divvied up around the world.新冠疫苗在全球是如何分配的。
Nature. 2020 Nov 30. doi: 10.1038/d41586-020-03370-6.
3
Emergency Use Authorization of Covid Vaccines - Safety and Efficacy Follow-up Considerations.新冠疫苗的紧急使用授权——安全性和有效性随访考量
危地马拉各市政当局民众中与新冠疫苗接种相关的社会人口因素
Vaccines (Basel). 2023 Mar 28;11(4):745. doi: 10.3390/vaccines11040745.
4
Global pattern and determinants of coronavirus disease 2019 (COVID-19) vaccine coverage and progression: a global ecological study.2019冠状病毒病(COVID-19)疫苗接种覆盖率及进展的全球模式与决定因素:一项全球生态学研究
Glob Health J. 2023 Mar;7(1):18-23. doi: 10.1016/j.glohj.2023.02.003. Epub 2023 Feb 9.
5
Vaccination, life expectancy, and trust: patterns of COVID-19 and measles vaccination rates around the world.疫苗接种、预期寿命和信任:全球 COVID-19 和麻疹疫苗接种率的模式。
Public Health. 2022 Sep;210:114-122. doi: 10.1016/j.puhe.2022.06.027. Epub 2022 Jul 4.
6
Assessing Inequities in COVID-19 Vaccine Roll-Out Strategy Programs: A Cross-Country Study Using a Machine Learning Approach.评估新冠疫苗接种策略项目中的不平等现象:一项使用机器学习方法的跨国研究
Vaccines (Basel). 2022 Jan 26;10(2):194. doi: 10.3390/vaccines10020194.
N Engl J Med. 2020 Nov 5;383(19):e107. doi: 10.1056/NEJMp2031373. Epub 2020 Oct 16.
4
Immune life history, vaccination, and the dynamics of SARS-CoV-2 over the next 5 years.未来 5 年的免疫史、疫苗接种和 SARS-CoV-2 的动态。
Science. 2020 Nov 13;370(6518):811-818. doi: 10.1126/science.abd7343. Epub 2020 Sep 21.
5
Vaccines for COVID-19.COVID-19 疫苗。
Clin Exp Immunol. 2020 Nov;202(2):162-192. doi: 10.1111/cei.13517. Epub 2020 Oct 18.
6
Review of Current Vaccine Development Strategies to Prevent Coronavirus Disease 2019 (COVID-19).2019年冠状病毒病(COVID-19)当前疫苗研发策略综述
Toxicol Pathol. 2020 Oct;48(7):800-809. doi: 10.1177/0192623320959090. Epub 2020 Sep 14.
7
COVID-19 Vaccine: A comprehensive status report.新型冠状病毒肺炎疫苗:全面现状报告。
Virus Res. 2020 Oct 15;288:198114. doi: 10.1016/j.virusres.2020.198114. Epub 2020 Aug 13.
8
Impact of Vaccines; Health, Economic and Social Perspectives.疫苗的影响;健康、经济和社会视角。
Front Microbiol. 2020 Jul 14;11:1526. doi: 10.3389/fmicb.2020.01526. eCollection 2020.
9
Vaccines for COVID-19: The current state of play.COVID-19 疫苗:当前进展状况。
Paediatr Respir Rev. 2020 Sep;35:43-49. doi: 10.1016/j.prrv.2020.06.010. Epub 2020 Jun 18.
10
The Equitable Distribution of COVID-19 Therapeutics and Vaccines.新冠治疗药物和疫苗的公平分配
JAMA. 2020 Jun 23;323(24):2462-2463. doi: 10.1001/jama.2020.6641.